GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » 9-Day RSI

TCR2 Therapeutics (TCR2 Therapeutics) 9-Day RSI : 8.17 (As of May. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-06), TCR2 Therapeutics's 9-Day RSI is 8.17.

The industry rank for TCR2 Therapeutics's 9-Day RSI or its related term are showing as below:

TCRR's 9-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 50.86 vs TCRR: 8.17

Competitive Comparison of TCR2 Therapeutics's 9-Day RSI

For the Biotechnology subindustry, TCR2 Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TCR2 Therapeutics's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where TCR2 Therapeutics's 9-Day RSI falls into.



TCR2 Therapeutics  (NAS:TCRR) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TCR2 Therapeutics  (NAS:TCRR) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


TCR2 Therapeutics 9-Day RSI Related Terms

Thank you for viewing the detailed overview of TCR2 Therapeutics's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Binney Street, Suite 710, Cambridge, MA, USA, 02142
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison officer: Chief Business & Strategy C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel director, officer: President & CEO C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju officer: Chief Technical Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice officer: Chief People Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan officer: Chief Financial Officer GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya officer: Chief Financial Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142